（於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 自願公告 硼中子治療裝置成功實現首次出束 本自願公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司， 統稱為「本集團」）作出，以知會本公司股東及潛在投資者有關本集團的最新業務 發展情況。 1 此次出束成功，驗證了系統核心部件各項參數均達到設計指標，標誌著該項目正 式從設備安裝正式轉入束流調試。這一關鍵節點的達成，為後續中子注量率精準 調控、束流物理驗證以及生物學效應評估等核心工作奠定了堅實基礎，也確保了 設備能夠按既定計劃高標準推進臨床治療，為癌症患者提供安全及精准的硼中子 治療服務。 承董事會命 中國生物科技服務控股有限公司 本集團位於中國海南博鰲樂城國際醫療旅遊先行區之旗艦項目 — 鵬博（海南）硼 中子醫 ...

Market Overview - The Hang Seng Index closed at 26,572 points, down 500 points or 1.9% from the previous day, with a total turnover of HKD 232.79 billion, a decrease of 14% day-on-day[6]. - Year-to-date performance shows the Hang Seng Index has increased by 31.81%, while the Financial Index has risen by 19.00%[4]. Sector Performance - Technology stocks faced significant declines, with Baidu down 7.2%, JD Group down 6.0%, and Alibaba down 4.4%[6]. - Conversely, pharmaceutical stocks performed well, with Wangshan Wangshui up 23.9%, Gilead Sciences up 15.5%, and Laika Pharmaceuticals up 12.2%[6]. Economic Indicators - The unemployment rate is expected to decrease, although some scholars view this as overly optimistic[3]. - Foreign investment in Chinese stocks reached nearly HKD 400 billion in the first ten months of the year[3]. Company News - Financial One Account (6638.HK) announced that its privatization plan has been approved by the court, expected to take effect on November 19[6]. - Hope Education International Holdings (1765.HK) is selling its 100% stake in Xi'an Benos Education Management for RMB 10 million, with a total cash settlement of RMB 380 million[6]. Global Market Trends - The Dow Jones Industrial Average closed at 47,147 points, down 309 points or 0.65%, while the S&P 500 fell by 0.05% to 6,734 points[6]. - The Nasdaq Composite rose by 0.13% to 22,900 points, indicating mixed performance among major U.S. indices[6]. Commodity Prices - New York crude oil prices increased by 2.39% to USD 60.09 per barrel, while Brent crude rose by 2.19% to USD 64.39 per barrel[4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 2025 ASN最新突破性專場|君聖泰醫藥展示HTD1801腎臟獲益數據 本公告由君聖泰醫藥（「本公司」，連同其附屬公司統稱為「本集團」）自願發佈，以 告知本公司股東及潛在投資者有關本集團的最新業務發展。 結果顯示，在輕度腎功能損害患者中，與安慰劑相比，HTD1801可顯著改善 eGFR，治療期間eGFR斜率呈正值；在超濾過患者中，HTD1801可相較安慰劑降 低eGFR，提示其可能促進腎功能恢復正常狀態。此外，HTD1801對血壓、血鈉 及血鉀等指標未見不良影響。 摘要標題：HTD1801在輕度腎功能損害患者中的腎臟獲益 報告編號：TH-PO1190 報告時間：2025年11月6日10:00 AM-12:00 PM 形式：壁報 1 作者：Filip Surmont, MD; Leili G ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本公告全部或任何部分內容而產生或因依賴該等內容引致的任何損失承擔任何責任。 本公告並非招股章程。有意投資者應先細閱蘇州旺山旺水生物醫藥股份有限公司（「本公司」）所 刊發日期為2025年10月28日的招股章程（「招股章程」）有關下文所述全球發售的詳細資料，方 始決定是否投資於其所發售的H股。本公司並無亦不會根據1940年美國《投資公司法》（經修訂） 登記。 除非本公告另有界定，否則本公告所用詞彙與招股章程所界定者具有相同涵義。 就全球發售而言，中信里昂證券有限公司作為穩定價格操作人（「穩定價格操作人」）或代其行 事的任何人士均可在市場上購買、超額分配股份或進行交易或以其他方式進行該等穩定價格行 動，以在上市日期後一段有限期間內穩定或維持H股的市價高於原應達至的水平。任何有關穩 定價格行動將遵照所有適用法律及監管規定進行，包括《證券及期貨條例》項下的《證券及期貨 （穩定價格）規則》。然而，穩定價格操作人或代其行事的任何人士並無義務進行 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 CStonePharmaceuticals 基石藥業宣佈CS2009（PD-1/VEGF/CTLA-4三特異性抗體）Ⅱ期臨床試驗聯合療法IND在中國 獲批，深入探索三抗治療潛力 本公告乃由基石藥業(「本公司」連同其附屬公司統稱「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 …………………………………………………………………………………………… 基石藥業今日宣佈CS200 ...

Group 1: Hang Seng Index (HSI) Analysis - The Hang Seng Index (HSI) experienced a slight increase of 0.72%, closing at 25,967 points, just below the 26,000 mark [1] - Market sentiment is mixed, with both bullish and bearish perspectives present, which is a normal market phenomenon [1] - Technical signals indicate a predominance of "sell" signals, with 8 sell signals compared to 6 buy signals, suggesting a cautious outlook [1] - The support level for HSI is around 25,400 points; if it falls below this, it may drop further to 24,600 points [2] - The resistance level is approximately 26,500 points, and investors are advised to consider bear certificates with a redemption price around 26,400 points [2] Group 2: JD Group (09618) Analysis - JD Group's stock closed at 128.7 yuan, with a support level at 124.3 yuan; a drop below this could lead to further declines to 117.7 yuan [9] - Some investors anticipate a rise to around 130 yuan before considering bearish positions, aligning with the current technical signals that favor buying [10] - The short-term resistance level for JD is approximately 135 yuan, indicating potential upward movement before any bearish actions [10] Group 3: WuXi Biologics (02269) Analysis - WuXi Biologics' stock has shown a slight decline with increased trading volume, indicating a potential buying opportunity [15] - The current support level is around 33.8 yuan; if this level is breached, the stock may drop to 30 yuan [15] - Despite the bearish sentiment, short-term technical signals are predominantly "buy," suggesting a favorable buying atmosphere [15] Group 4: Baidu Group (09888) Analysis - Baidu's stock is in a stable consolidation phase, with a support level at 111.3 yuan; a drop below this could lead to further declines to 98.4 yuan [21] - The short-term technical signals favor buying, with 10 buy signals against 5 sell signals, indicating potential for upward movement [21] - Investors are advised to consider bull certificates with a redemption price around 80 yuan for added safety [21] Group 5: China Unicom (00762) Analysis - China Unicom's stock closed at 9.39 yuan, near the upper limit of the Bollinger Bands, with a resistance level at 9.67 yuan [27] - A breakthrough of the 9.67 yuan resistance could lead to further increases towards 9.85 yuan, but reaching 10 yuan may take time [27] - The short-term technical signals are neutral, indicating no clear direction for price movement [27] Group 6: Li Ning (02331) Analysis - Li Ning's stock has shown strong performance, with a resistance level at 19.6 yuan; breaking this could lead to further increases towards 19.8 yuan [33] - The current technical signals are neutral, suggesting a lack of clear upward or downward momentum [33] - Investors are encouraged to monitor market trends and consider various sources of information for informed decision-making [33]

（股份代號：2453） 自願公告 與大興發展租賃達成融資合作 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發，以知會本公司股東及潛在投資者有關本集團的最新業務發展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 通過與專業融資租賃公司合作，本公司將進一步拓展融資管道，豐富公司的資金 來源，為未來業務發展中的資金需求提供更多保障，同時也有助於公司與行業內 專業機構建立長期合作關係，為後續合作奠定基礎。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生；及(iii) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 基石 藥業將攜 C S 2 0 1 5 （ O X 4 0 L / T S L P雙特 異性抗體 ）亮相 A C A A I 2 0 2 5 本公告乃由基石藥業(「本公司」連同其附屬公司統稱(「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 …………………………………………………………………………………………… 基石藥業今日宣佈公司自身免疫與炎症領域管線之一CS2015（ ...

Group 1 - The pharmaceutical sector has outperformed the market, with stock prices increasing between 60% to 100% in the first half of the year [1] - The export value of innovative drugs in the first half of the year has already reached the total amount of the previous year [1] - The stock price of CSPC Pharmaceutical Group (01093) has shown strong performance, reaching HKD 10.27, up 6.10% with a trading volume of HKD 14.29 billion [2] Group 2 - Technical indicators for CSPC indicate a bullish trend, with MACD maintaining a buy signal and RSI rising to 61, entering a strong zone [2] - Key price levels for CSPC include a psychological support at HKD 9 and a short-term target at HKD 10.42, with a potential challenge at HKD 11.4 [2] - The performance of related derivatives has shown significant leverage effects, with call warrants outperforming the underlying stock [4] Group 3 - Two notable call warrants for CSPC are available: one with a strike price of HKD 10.88 and a leverage of 3.6 times, and another with a strike price of HKD 10.95 and a leverage of 3.1 times [7] - Investors are considering whether the recent price increase for CSPC is a short-term rebound or the start of a medium to long-term trend [9]

Group 1 - The Hang Seng Index (HSI) has seen bearish investors continuously for three days, indicating a potential decline for at least a week, with a recall price of 24,498 for bear certificates [1] - Investors are deploying bull certificates towards the end of trading sessions, betting on the next day's market movements, which reflects a common overnight holding strategy [2] - Technical analysis suggests that the HSI is currently above 24,000, with support at 23,618 and resistance at 24,542, indicating a "buy" signal [2] Group 2 - Hua Hong Semiconductor (01347.HK) has a strong buy signal, with resistance levels at 38.6 and 41.5, while investors are eyeing a potential rise to 44 [4] - WuXi Biologics (02269.HK) is stabilizing at a closing price of 25.65, with neutral technical signals and resistance at 26.8 and 29, while support is at 23.9 [7] - BYD Electronic (00285.HK) shows a buy signal, with a target of 40, but requires breaking through resistance levels at 32.8 and 33.9 [10] Group 3 - Meituan-W (03690.HK) has bearish investors anticipating a drop below 90 before entering the market, with some considering put options [12] - NetEase-S (09999.HK) is on an upward trend, with resistance at 219 and 229, while investors are cautious about the safety of a bear certificate with a recall price of 220 [14]